Facial Injuries and Disorders
Methodology & AI Transparency ⓘ
Facial Injuries and Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Face injuries and disorders can cause pain and affect how you look.
- 2 Real-world patient consensus: Mapped to Ear, Nose, Throat & Oral Health under ICD-10-CM J35.7 for Facial Injuries and Disorders clinical workups.
- 3 Typical cash cost range: Workup highlights for Facial Injuries and Disorders (J35.7): hearing protection/amplification [Facial Injuries and Disorders J35.7].
- 4 Top reported side effects / signs: Longitudinal Facial Injuries and Disorders monitoring tracks Pure-Tone Audiometry & in Facial Injuries and Disorders (J35.7: Tympanometry) toward Thresholds <= 20 dB HL; normal middle-ear pressure (J35.7).
Ask our AI Specialists anything about Facial Injuries and Disorders
What Is Facial Injuries and Disorders?
Face injuries and disorders can cause pain and affect how you look. In severe cases, they can affect sight, speech, breathing and your ability to swallow. Fractures (broken bones), especially in the bones of your nose, cheekbone and jaw , are common facial injuries. Certain diseases also lead to facial disorders. For example, nerve diseases like trigeminal neuralgia or Bell's palsy sometimes cause facial pain, spasms and trouble with eye or facial movement. Birth defects can also affect the face. They can cause underdeveloped or unusually prominent facial features or a lack of facial expression. Cleft lip and palate are a common facial birth defect.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Facial Injuries and Disorders (J35.7) center on middle-ear effusion/infection [Facial Injuries and Disorders J35.7]. Cross-referenced with NIH MeSH (Craniofacial Abnormalities, Facial Injuries), targeted ent & hearing interventions aim to normalize Pure-Tone Audiometry & in Facial Injuries and Disorders (J35.7: Tympanometry).
Common Symptoms & Clinical Signs
- • Presentation of Facial Injuries and Disorders (J35.7): episodic spinning vertigo in Facial Injuries and Disorders (J35.7: accompanied by fluctuating)
- • Secondary Facial Injuries and Disorders clinical sign: bleeding or receding in Facial Injuries and Disorders (J35.7: gums, tooth sensitivity,)
- • Symptom flares in Facial Injuries and Disorders correlating with Pure-Tone Audiometry & in Facial Injuries and Disorders (J35.7: Tympanometry) deviation outside Thresholds <= 20 dB HL; normal middle-ear pressure (J35.7)
- • Functional ent & hearing impact requiring hearing protection/amplification [Facial Injuries and Disorders J35.7] evaluation (J35.7)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Facial Injuries and Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J35.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Facial Injuries and Disorders (J35.7: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (J35.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Facial Injuries and Disorders (J35.7: & Bleeding Index) | Probing <= 3 mm without bleeding (J35.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Facial Injuries and Disorders
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Oxymetazoline Hydrochloride Nasal, Afrin No Drip Original Pump Mist • RxCUI 1869816 | Vasoconstrictor | 82% | $19.6884 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Facial Injuries and Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. Journal of cosmetic dermatology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40968493 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two In ULTRA I and ULTRA II, the safety and real-world benefits of incobotulinumtoxinA for the simultaneous treatment of moderate-to-severe UFLs were demonstrated, with significant improvements. Aesthetic surgery journal • 2025-02-18 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39475143 ↗ |
| Can This Approach Help? Inside the Latest Research on Validation of the Index for Facial Angiofibromas: Data analysis from a randomized The IFA score is potentially clinically useful because of its high validity and reliability. The Journal of dermatology • 2024-06-15 • Phase III Randomized Trial | N = 62 | 88/100 | PMID 38619178 ↗ |
| Can This Approach Help? Inside the Latest Research on Facial tolerability studies comparing gel formulations of retinoids used to treat A second study compared once-daily versus alternate-day tazarotene 0.1% gel therapy. Cutis • 2001-06-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 11499328 ↗ |
Facial Injuries and Disorders Patient Community & “People Like Me” Threads
Filter Facial Injuries and Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.